BioNTech SE
corporate_fare Company Profile
BioNTech SE (NASDAQ:BNTX) is a publicly traded company in the Life Sciences sector. Wiseek monitors BNTX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- BioNTech Commences $1 Billion Share Repurchase Program
- Pumitamig Shows Encouraging Phase 2 Efficacy in Lung Cancer, Advancing to Pivotal Phase 3
- BioNTech & BMS Pumitamig Shows Encouraging Phase 2 Efficacy in NSCLC, High Response Rates Across PD-L1 Levels
- BioNTech Pre-Announces Positive Late-Stage Oncology Data for Pumitamig and Gotistobart at ASCO
- BioNTech's Late-Stage Oncology Drugs Pumitamig, Gotistobart Show Encouraging Data at ASCO
Financial Snapshot
Insider Transactions
BNTX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.